403results about How to "Reduce healing" patented technology

A photo-thermal therapeutic device having an outer housing that can be used to treat patients. A plurality of light emitting diodes and resistors are resiliently mounted in the housing. The resilient mounting of the diodes and resistors allow the device to conform and provide effective treatment of almost any surface of the body of a user.

This invention is directed to improved compositions for treatment of acne and related methods. In some embodiments, the present invention is directed to compositions comprising a topical vehicle, nanosilver, acne medicine and soothing agents, effective for treating acne without irritation.

The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the prenetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbiocide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of entero-bacteria, and to less than 1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days.

A cosmetic treatment apparatus comprises a discharge lamp, a capacitor, and a current controller. The capacitor supplies an electric current for the discharge lamp. The current controller controls the electric current flowing from the capacitor to the discharge lamp. In a first stage of the cosmetic treatment, the current controller performs a constant current control operation. In this operation, the current flowing to the lamp does not vary with variations of the capacitor voltage. In the end stage of the treatment, the current is lower, and it decreases with the capacitor voltage.

The invention discloses the application of LncRNA-GAS5 in preparing a glaucoma diagnosis reagent and a glaucoma lesion diagnosis reagent kit. Through high-throughput sequencing and quantitative PCR validation, it is found that the LncRNA-GAS5 has a significant correlation with the occurrence of glaucoma. The LncRNA-GAS5 can be used for screening clinical glaucoma patients and providing a theoretical basis for early intervention in glaucoma.

The invention relates to caffeine electronic cigarette liquid, which mainly comprises 3-5%w/v of tobacco leaf extract, 5-10%w/v of pure water, 3-5%w/v of tobacco essence, 0.1-3%w/v of guarana extract with 5% in concentration, 0.2-1%w/v of stabilizer, 3-8%w/v of thickening agent and the balance of propylene glycol. The invention uses caffeine instead of nicotine; and the caffeine is an excitant for the central nervous system, and can increase the content of adenosine cyclophosphate (cAMP) in the cells. A small or medium amount of caffeine taken can excite the cerebral cortex, boost spirits of the people, enhance the attention, self-confidence, working efficiency and enthusiasm, shorten the time for selection and response and improve the recognition capability and instantaneously oral memory. In addition, the caffeine can promote synthesis and release of catecholamine, have positive effects to the cardiovascular system, promote gastric acid secretion, reduce the gallstone morbidity, and treat hemicrania and the like.

A method for local treatment of a target region of tissue within a body of a subject includes navigating a first probe (210, 310) intra-bodily to a first location within the body of the subject and employing the first probe to locally change at least one characteristic of a selected region of tissue. Either the same probe (210, 310) or another probe (250, 330) is employed to apply a treatment to the target region of the body of the subject. The changed characteristic of the selected region of tissue is chosen so as to enhance at least one parameter of the treatment.

The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).

The invention discloses a compound preparation of piperacillin sodium and tazobactam sodium for injection, which comprises piperacillin sodium and tazobactam sodium by the weight ratio of 3-4:0.8-1.2. The preparation can be used for treating respiratory system infection, urological infection, otologia infection and skin infection.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs that works via GABA receptor agonism. Preferably the AED is stiripentol. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

There is provided a process for the thermal treatment of waste materials, particularly pharmaceutical waste materials. The process comprises placing the waste material into a chamber and increasing the temperature inside the chamber in three stages. At a first stage, water in the material is desorbed as water vapor. At a second stage, organic ingredients in the material are desorbed and decomposed producing condensable organic vapor and non-condensable synthesis gas. And at a third stage, polymer-based components of the material are depolymerized and decomposed producing condensable hydrocarbon vapor. The non-condensable synthesis gas produced can be used as heating source for the process.

The invention discloses a combination process of nicotinamide riboside and its derivative with pyrroloquinoline quinone and its sodium salt. The combination process includes: combining any two or three of or all of NR (nicotinamide riboside) (a chloride, or nicotinamide riboside), NMN (beta-nicotinamide mononucleotide), NADH (nicotinamide adenine dinucleotide) and PQQ (pyrroloquinoline quinone disodium salt) into a formulation for making foods, health foods, cosmetics or drugs; the formulation is injected into the human body in external application, oral application or injection manner to takeeffect. The nicotinamide riboside and its derivative function to defy age; the pyrroloquinoline quinone and its sodium salt have the like function and are functionally complementary to nicotinamide riboside; the nicotinamide riboside or its derivative is combined with pyrroloquinoline quinone or its sodium salt into a formulation for making products, such as food additives, health foods, cosmetics and drugs, thereby delaying human senility, maintaining beauty or treating diseases.

The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application and ease of use. The compounds can be used in pharmaceutical compositions for the treatment of involuntary muscle spasms and neuropathic pain and in cosmetic compositions for the treatment of facial wrinkles. Also provided are kits useful for therapeutic and/or cosmetic applications.

The invention discloses a compound probiotic preparation for preventing and treating piglet diarrhea and a preparation method and application. The compound probiotic preparation is prepared from clostridium butyricum, lactobacillus reuteri and bifidobacterium longum, wherein the total quantity of viable bacteria in the compound probiotic preparation is 10<1> to 10<20> per ml. The compound probiotic preparation disclosed by the invention has the advantages that the diarrhea rate and the death rate of weaned piglets are remarkably reduced. On the sixth to twentieth day of the age in days of the piglets, the prepared compound probiotic preparation is irrigated into stomachs of 66 large binary hybrid piglets, the irrigation dosage is 5 to 10ml/time, and the piglets are irrigated once every day. Compared with a control group irrigated by a Phosphate Buffer Solution (PBS), the compound probiotic preparation has the advantages that the diarrhea rate of the group irrigated by the compound probiotic preparation at the first to fifteenth day stage after weaning (21 days of age) is remarkably reduced by 87 percent, and the death rate is reduced by 70 percent. The compound probiotic preparation effectively prevents the piglet diarrhea.

A composite suppository for treating pile, phlebitis and phlebeurysma is prepared from micro-granular diosmin and hesperidin, matrix for suppository and additive.

The invention especially relates to molecular markers, internal reference genes and application thereof, a detection kit and a method for constructing a detection model, belonging to the field of biotechnology. With follow-up information used for comparison, the kit provided by the invention has accuracy of 70% in predication of the risk of recurrence or death of first-visit patients with ER-positive and PR-positive breast cancers in 3-10 years after operations, wherein the prediction accuracies of a low-risk group and a high-risk group are 81.1% and 54.4%, respectively while the prediction accuracies of corresponding FFPE pathological examination results are 71.9 to 56.8%, respectively. The risk prediction model matching with the kit only needs the Ct values of the molecular markers, theage of a patient, the stage of pT and the number of LN and does not depend on other clinical pathological information, so the risk prediction model has better performance in evaluation of prognosis ofbreast cancers than simple pathological prediction results, can reduce malpractice caused by errors in pathological prediction and further improves a technical method for evaluation of prognosis of breast cancers.

A pharmaceutical composition is an organic salt formed by an organic acid rosuvastatin and an organic base azelnidipine with a molar ratio of 1:1. The pharmaceutical composition can be made into any dosage forms together with a pharmaceutically-acceptable carrier for reducing blood pressure and blood lipid, reducing myocardial infarction and treating cerebral apoplexy. The inventive pharmaceutical composition has the advantages of stable physiochemical indexes, controllable product quality, and convenient administration.

The invention provides a near-infrared light therapeutic apparatus which comprises a light source capable of emitting near-infrared light, a carrier of the light source, a semispherical face support for fixing the carrier, a driver for driving the light source to emit light, a signal controller for providing a control light source for the driver, a man-machine interaction module for information input and output of a whole system and a power source module. The man-machine interaction module is connected with the input end of the controller. The output end of the controller is connected with the input end of the driver, and the output end of the driver is connected with the light source. The power source module is connected with the driver, the controller and the man-machine interaction module. The irradiation range of the light source covers the whole forehead, is downwards flush with the brow ridge, surrounds the temples, the head top and the back side of the head, and is downwards flush with the upper edge of the neck. The wavelength of the light source ranges from 600 nm to 900 nm. According to the near-infrared light therapeutic apparatus, the near-infrared light is originally introduced into treatment of head functional diseases, and the brain functional disease treatment apparatus which is free of wounds, low in cost, convenient to use and practical is provided.

The invention discloses a Chinese medicinal composition for treating gout and a preparation method thereof and belongs to the technical field of medicines. The Chinese medicinal composition is prepared from the following raw materials in parts by weight: 10-50 parts of edible tulip, 10-20 parts of notopterygium root, 5-20 parts of Chinese angelica, 5-15 parts of rhizoma smilacis glabrae, 5-10 parts of dried rehmannia, 5-15 parts of longhairy antenoron herb, 5-15 parts of honeysuckle, 1-10 parts of radix clematidis, 5-15 parts of medlar, 9-15 parts of the root of bidentate achyranthes, 9-15 parts of szechuan lovage rhizome, 5-15 parts of angelica root, 0.2-9 parts of kudzuvine root, 5.5-15 parts of white paeony root, 6-9 parts of glossy privet fruit and 10-15 parts of licorice root. The Chinese medicinal composition has the good treatment effect in treatment or prevention of gout, low side effects of the medicine and obvious clinical promotional value.

The invention provides a medicine composition used for treating cardio-cerebrovascular and a preparing method thereof in order to overcome the defects of large dosage and indefinite mechanism of effective components of the existing Chinese medicine preparation used for treating the cardio-cerebrovascular. The medicine composition is made of medicine materials comprising the monomer compositions of ginsenoside and astragalus saponin and excipient and is prepared by conventional preparation technology. Compared with prior art, the medicine composition of the invention has definite components, reliable curative effect, small dosage and manageable quality, so the medicine composition can effectively treat the cardio-cerebrovascular.

The invention provides an auxiliary diagnosis method and device, and a computer device. The method comprises steps that at least one description keyword is determined based on condition description data of a user; the diagnosis result including target diagnosis keywords is determined for the user according to the at least one description keyword and a preset disease diagnosis knowledge database, and the condition diagnosis knowledge database includes a correspondence between the at least one condition keyword and the diagnosis keywords; the diagnosis result is displayed to the user.

The present invention is directed to methods of treating diseases and disorders of the skin (e.g., acne) with heat-enabled photodynamic therapy (HEPT). Methods of treating acne, non-melanoma skin cancer (NMSC), actinic keratosis (AK) or disseminated superficial actinic porokeratosis (DSAP) using red light photodynamic therapy on heat-treated skin.

The invention relates to mitochondrial-targeting protein nanoparticles, and relates to an amino acid sequence, a coding nucleic acid sequence, a vector of the coding nucleic acid, host expression bacteria and other related information. Under the induction of metal ions, the self-assembled protein nanoparticles can be obtained by an escherichia coli expression system. The protein nanoparticles canbe applied in cancer diagnosis and treatment. Compared with conventional mitochondrial-targeting small molecules (TPP, MPP and the like), the protein nanoparticles can achieve properties of tumor enrichment, mitochondrial targeting, causing of increase of the ROS content in cells, induction of cell apoptosis, inhibition of tumor growth and the like.